Enodia Raises Seed Funding to Advance Protein Degradation Platform

Argobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learning

Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Enodia Financing co-led by Elaia, Pfizer Ventures...

Enodia Therapeutics raises €20.7m seed round for targeted protein degradation pipeline - European Biotechnology Magazine

Paris-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the Seed financing under the InnoBio investment framework, with further contributions from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital. The post Enodia Therapeutics raises €20.7m seed ro…

Enodia raises seed funding to advance protein degradation platform

Enodia Therapeutics has raised $25m in seed funding to advance a small-molecule platform for targeted protein degradation using proteomics and machine learning.The post Enodia raises seed funding to advance protein degradation platform appeared first on Medical Device Network.